Literature DB >> 2669847

The protease inhibitor, alpha 1-antichymotrypsin, is a component of the brain amyloid deposits in normal aging and Alzheimer's disease.

C R Abraham1, H Potter.   

Abstract

The purpose of this study was to characterize the nature and the origin of the Alzheimer's disease amyloid deposits. We used an amyloid antiserum to screen a human liver expression library. A positive clone was sequenced and found to code for the serine protease inhibitor alpha 1-antichymotrypsin, an acute phase serum protein. Thus, this protein is a second component of the brain amyloid in addition to the beta-protein. In order to determine whether the inhibitor originated from the serum or was made in the brain, we performed Northern blots on tissue from control and Alzheimer brain and found that alpha 1-antichymotrypsin RNA is present in the brain and that the diseased brain contained larger amounts than the controls. Immunocytochemistry and in situ hybridization show the astrocytes to produce the inhibitor, mainly around senile plaques, alpha 1-antichymotrypsin is only associated with the amyloid deposits of the beta-protein kind in normal aging of man and monkeys. Alzheimer's, Down's syndrome and hereditary cerebral hemorrhage with amyloidosis of Dutch origin, but not in primary and secondary amyloidosis or familial amyloidotic polyneuropathy. The specific association between alpha 1-antichymotrypsin and the beta-protein prompted us to suggest a role for this serine protease inhibitor in the proteolytic processing of the beta-protein precursor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2669847     DOI: 10.3109/07853898909149188

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  6 in total

1.  Measurement of acute phase proteins in the rat brain: contribution of vascular contents.

Authors:  D A Loeffler; M C Linder; M Zamany; E Harel; M A Paul; H Baumann; P A LeWitt
Journal:  Neurochem Res       Date:  1999-10       Impact factor: 3.996

2.  Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Authors:  Natalia Mast; Aicha Saadane; Ana Valencia-Olvera; James Constans; Erin Maxfield; Hiroyuki Arakawa; Young Li; Gary Landreth; Irina A Pikuleva
Journal:  Neuropharmacology       Date:  2017-06-24       Impact factor: 5.250

3.  2008 Landis Award lecture. Inflammation and the autodigestion hypothesis.

Authors:  Geert W Schmid-Schönbein
Journal:  Microcirculation       Date:  2009-05       Impact factor: 2.628

4.  Revelation of Pivotal Genes Pertinent to Alzheimer's Pathogenesis: A Methodical Evaluation of 32 GEO Datasets.

Authors:  Hema Sree Gns; Saraswathy Ganesan Rajalekshmi; Raghunadha R Burri
Journal:  J Mol Neurosci       Date:  2021-10-19       Impact factor: 2.866

5.  Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.

Authors:  Alex E Roher; David H Cribbs; Ronald C Kim; Chera L Maarouf; Charisse M Whiteside; Tyler A Kokjohn; Ian D Daugs; Elizabeth Head; Carolyn Liebsack; Geidy Serrano; Christine Belden; Marwan N Sabbagh; Thomas G Beach
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

6.  Computational interaction analysis of organophosphorus pesticides with different metabolic proteins in humans.

Authors:  Amit Kumar Sharma; Karuna Gaur; Rajeev Kumar Tiwari; Mulayam Singh Gaur
Journal:  J Biomed Res       Date:  2011-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.